In 2021, Harvard and MIT partnered with Cytiva, Fujifilm Diosynth Biotechnologies and Alexandria Real Estate Equities to bring the best of academia, the life sciences industry, and world-class research hospitals together to accelerate life sciences innovation. Landmark Bio was established to break down the barriers in novel therapeutics development and industrialization. We collaborate with academics, startups and drug developers to take groundbreaking discoveries from bench to clinics by providing capacity and expertise in CMC development and manufacturing. Uniquely positioned as pre-platform and technology agnostic, we help design, de-risk, and develop early innovations into future platforms. Our cross-sector partnership offers an unparalleled academic, industry, hospitals and investor network with a magnetic pull to power biomanufacturing innovation. As a mission-driven organization, we embrace risk and opportunities at the bleeding-edge in order to advance emerging technologies, demonstrate therapeutic potential and improve human health.